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Abstract
Background: Cancer is a disease of genome alterations that arise through the acquisition of multiple somatic DNA
sequence mutations. Some of these mutations can be critical for the development of a tumor and can be useful to
characterize tumor types or predict outcome.
Description: We have constructed an integrated biological information system termed the Roche Cancer Genome
Database (RCGDB) combining different human mutation databases already publicly available. This data is further
extended by hand-curated information from publications.
The current version of the RCGDB provides a user-friendly graphical interface that gives access to the data in
different ways: (1) Single interactive search by genes, samples, cell lines, diseases, as well as pathways, (2) batch
searches for genes and cell lines, (3) customized searches for regularly occurring requests, and (4) an advanced
query interface enabling the user to query for samples and mutations by various filter criteria.
Conclusion: The interfaces of the presented database enable the user to search and view mutations in an intuitive
and straight-forward manner. The database is freely accessible at http://rcgdb.bioinf.uni-sb.de/MutomeWeb/.
Background
Facilitated by the development of new high throughput
techniques like SNP arrays the identification of genes
involved in complex diseases such as cancer has made
enormous progress over the recent years. This resulted
in a huge amount of information on human genetic var-
iations which have been described in various genes asso-
ciated with a wide variety of diseases [1-3]. Sequence
variations are being studied for a better understanding
of the mechanism and development of cancer as a
mutation-driven disease [4]. Furthermore, somatic muta-
tions in cancer can be used in clinical studies and mole-
cular pathology to characterize tumor types, to predict
response to treatment, and to find the best suited treat-
ment. Thus, mutation analysis can play an important
role in drug discovery and personalized healthcare.
The proportion of mutations causally implicated in
cancer is still unknown especially due to the high num-
ber of mutations between different tumors [5-8].
Although the number of unique variations for each can-
cer genome can be very high [9,10], only a few somatic
variations will be critical for the development of the
tumor. These causative variations, the so-called “dri-
vers”, are emerging because of selective pressure during
tumorigenesis, whereas many mutations are only inci-
dental or caused by genome instabilities, so-called “pas-
sengers” [11]. The differentiation of disease-causing
driver mutations from passenger variations is a chal-
lenge for mutation analysis [12].
Despite the technological progress and increase of
data, the benefit of this information is still limited due
to the ever increasing number of databases [13] and the
absence of a unified access to the mutation data. Cur-
rently, researchers are typically forced to browse several,
often highly specialized databases to obtain the required
information. A more complete understanding of rela-
tions and dependencies between mutations and cancer,
however, requires the availability of an efficient integra-
tive cancer genome information system.
Methods
To facilitate the analyses of cancer mutations, we devel-
oped the second version of the Roche Cancer Genome
Database (RCGDB) [14], an integrative biological infor-
mation system combining different databases which are
already publicly available. We use the concept of a data
warehouse with a single database containing all informa-
tion presented by the system. To this end, we developed
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tion and implemented different importer routines to
map external database information onto our model.
In the current version the RCGDB combines a huge
variety of information on the human cancer genome. We
integrated somatic mutations, which are not inherited
but acquired during lifetime in somatic cells of an organ-
ism and might cause tissue specific tumors. This infor-
mation is gathered from COSMIC at the Sanger Institute
[15], the Cancer Genome Atlas project [16], the IARC
TP53 database [17], OMIM [18], KinMutBase [19], and
the L1CAM mutation database [20]. From the Cancer
Genome Atlas we also integrated germline mutations
which in contrast to the somatic mutations can be found
in all cells of an organism including germ line cells.
Furthermore, we imported additional data from publica-
tions, which we curated by hand. For both types of muta-
tions, somatic and germline, we store all available sample
information like tissue of origin and histology of the sam-
ple, or if the sample was a tumor cell line.
In addition to germline and somatic mutations, we
retrieve SNPs and their corresponding frequencies from
the international HapMap project [21]. We focus only
o nt h eH a p M a pd a t as o u r c ef o rS N P sa n dd e c i d e dn o t
to integrate the dbSNP [22] since it contains too many
false positive SNPs. The HapMap data is integrated as a
third group of information, since for SNPs it is not
known whether the sample information is derived from
a tumor or a normal sample. Therefore, a correlation
between diseases and SNPs cannot be calculated.
Furthermore, our system contains amplification data
from the database of genomic variants and the NCBI
SKY/M-FISH & CGH database [23], as well as pre-ana-
lyzed amplification data from the Tumorscape project at
the BROAD institute [24].
The cancer genome data is further enriched by path-
way information from KEGG [25], BioCarta http://www.
biocarta.com and Roche internal networks.
Results
A major aspect in designing the user interface was that
users should be able to search and view mutations in an
intuitive and straight-forward manner, without having to
understand the architectural details of the warehouse
system. To facilitate this, we grant access to the RCGDB
via different ways:
Simple Search
First, the database offers a Google-like web interface to
search for cancer genome information on genes, sam-
ples, cell lines, diseases, as well as pathways. As a special
feature each search is supported by an auto-suggestion
f u n c t i o n a l i t ya l l o w i n g ,e . g .i nt h eg e n es e a r c h ,t oq u e r y
by NCBI GeneIDs, names, or synonyms.
After performing a simple gene search the system pre-
sents a single page with all gene centered information.
An example is shown in Figure 1. On the left-hand side,
general gene information (symbol, alias, description,
etc.) and mutation counts are presented in a card. The
right-hand side shows an overview of all somatic and
germline mutations based on the amino acid sequence
of the gene including a histogram representing the sam-
ple frequencies. Below this overview separate sections
each display a table of somatic mutations, germline
mutations, SNPs, amplification data, CGH data, and
SKY/M-FISH data. Each table features a filter function-
ality combined with an Excel export option.
For cell line queries we offer searches by cell line
name or frequently used synonyms. The resulting page
presents a card with general information on the sample
(name, synonyms, tissue, histology, etc.) on the left-hand
side. On the right-hand side, different sections display
all known cancer genome information for the sample.
This includes a list of all mutations and a table of all
mutated genes. Below that we give an overview of all
genes, which were found not to be mutated. For genes
not mentioned in one of these two sections the database
contains no mutation information for a given cell line.
In addition to the cell line search the RCGDB offers
an interface to query samples by tissue and histology.
The system will check all samples with the given filter
for mutations and present all non-mutated and mutated
genes in these samples. For each mutated gene we show
the percentage of mutated samples, allowing to filter for
the most mutated gene in the given tissue and histology.
Another possibility to query the system is given by the
disease search interface based on OMIM disease names
or IDs. After performing a search we present all genes
associated with this disease by OMIM and all HapMap
SNPs found in the region of these genes. These SNPs
are not directly associated with the given disease but
rather with a gene which is known to be associated with
the disease.
For researchers working on special pathways we inte-
grated KEGG and BioCarta pathways along with Roche
internal pathways. After selecting the desired pathway
we present a static pathway image where all genes are
linked to the corresponding gene search page. For pro-
tein families within KEGG pathways the system will
directly link to a gene batch search for all members of
the family.
Batch Search
The above-mentioned interfaces also allow batch
searches for genes, samples and cell lines whereby
multiple entries are separated by a single white space.
As a result, on the left-hand side the system presents
an overview of all matches found. If the search name
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single gene or cell line, the corresponding match is
shown. For ambiguous matches the user can refine the
search by selecting the desired gene or sample. This
directly updates the mutation findings presented on
the right-hand side, as well as the section on mutated
genes or mutated cell lines respectively (see Additional
file 1).
Smart Search
The second access point to the RCGDB are customized
search interfaces (so called smart searches) for regularly
occurring requests of higher complexity. The concept
behind the smart searches are specialized interfaces for
different applications, presenting the data in a highly
condensed way. An example is the “mutation status”
smart search as shown in Additional file 2. A classical
and often occurring request from biologists refers to the
mutation status of different genes in various cell lines.
For each gene/cell line combination the researchers
want to know if the gene is mutated or wildtype. For
this question, we offer a smart query with separate
input fields for genes and cell lines. Each input field has
t h es a m ea u t o - s u g g e s t i o nf e a t u r e sa sk n o w nf r o mt h e
simple search interfaces and allows for multiple entries
divided by spaces. In addition, each smart search inter-
face presents a short description to help the user find
the correct smart search fitting his purposes. As a result,
the mutation status smart search presents a matrix with
the genes as rows and cell lines as columns. For each
gene/cell line combination the matrix cell shows if the
gene is mutated (mut), wildtype (wt), or no information
is known in the database (na). Cards on the left-hand
side and right-hand side show if the cell line or gene
was found in the system or not. This is especially useful
if the user has pasted a number of genes or cell lines
into the interface without using the auto-suggestion
feature.
The smart searches are not only used for customized
search interfaces but also for integrative analyses. An
example for this is the pathway enrichment analysis
query (see Additional file 2, lower panel), which for all
KEGG pathways determines whether the number of
mutated genes found in a subset of samples is statisti-
cally significant. The subset of samples is specified in
the interface by the tissue and histology.
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Figure 1 Searching for cancer genome information of EGFR via the simple gene search interface. The results of the query are shown in
blue boxes in the lower part of the figure.
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Furthermore, we included a powerful advanced search
interface enabling the user to search for putative bio-
markers. This interface allows to query for samples and
mutations by various filter criteria, e.g. genes, samples,
tissue, histology, or mutation, without any restriction in
the number of filters. With the plus/minus sign one can
add/remove single filters interactively. A logical operator
can be selected for each filter allowing to add negative
and “like” searches. The input fields show the same
auto-suggestion features as known from the simple
search interfaces, depending on the selected filter type.
These fields also support multiple entries, which need to
be separated by whitespace, as well as multiple and sin-
gle character wildcards for “like” operators (see Addi-
tional file 3). After performing an advanced search all
somatic mutations, germline mutations, and samples ful-
filling the selected filter criteria are presented in sepa-
rate sections at the bottom of the page. An additional
statistics section shows a table with the counts of all
matched amino acid mutations. For each mutation we
also state the frequency of all samples, the frequency of
all samples with at least one mutation, as well as the
relative frequency at the given position.
Discussion
In order to provide a central resource for scientists in
the cancer research community, we developed the
RCGDB as a comprehensive resource of cancer genome
information. To date, a number of multi-gene locus-spe-
cific databases (LSDB) and single-gene LSDBs are pub-
licly available and offer different kinds of human
variation data by various interfaces. Unfortunately, the
diversity of mutation information systems and the
underlying data models make it difficult to mine human
variation databases in an integrative approach. Thus for
a comprehensive analysis of human variation data the
researcher still has to search multiple databases.
These drawbacks have been overcome by the integra-
tive concept underlying the RCGDB. The main idea
here is to offer data spanning a variety of data sources
and data types. The database not only offers the com-
plete data available in the integrated data sources, but in
addition includes mutation data from 14 publications
which were curated by hand. To the best of our knowl-
edge this data is currently not available in any one of
the other databases. The huge benefit of this concept is
illustrated in Table 1.
Another important feature of the RCGDB compared
to already published databases on human variation data
can be found in our powerful search interfaces: Muta-
tion databases offer mostly access via gene, sample and
tissue search, which we extend by batch searches and
additional pathway and OMIM disease searches. Our
advanced filter search and especially our smart searches
are very convenient and allow for full access to cancer
genome data. Users whose primary interest lies within a
specific biological problem will prefer the convenient
Google-like web interface or customized smart searches
providing powerful platform-independent visualization
of the data. The search pages accept names, synonyms,
or IDs and suggest potential matches by auto-comple-
tion. These suggestions during typing the search string
will be very helpful for users if the NCBI GeneID or the
exact scientific name of the gene is not known.
With the Roche Cancer Genome Database we already
cover a wide range of cancer related data and offer a
convenient way to use this data in an integrated fashion.
For the future, we will continue to integrate new exter-
nal cancer related data into the warehouse system. The
Roche Cancer Genome Database is publicly available at
http://rcgdb.bioinf.uni-sb.de/MutomeWeb/.
Table 1 Counts of the different mutations types grouped by source of origin
Release Somatic
mutations
Germline
mutations
SNPs Genetic Variants
(CGH)
Genetic Variants
(SKY/M-FISH)
Catalogue of somatic mutations in cancer
(COSMIC)
V43 19267 - - - -
OMIM - 2047 - - - -
The Cancer Genome Atlas MA files 18432 84113 - - -
IARC TP53 Database R14 3942 - - - -
KinMutBase V3.0 565 - - - -
University of Groningen L1CAM Mutation
DB
1.0 206 - - - -
International HapMap Project 27 - - 1657504 - -
Database of Genomic Variants V9 - - - 85193 -
NCBI SKY/M-FISH & CGH Database - - - - 3681 6377
Publications - 29159 5139 - - -
Total (in RCGDB) 73618 89252 1657504 88874 6377
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Additional file 1: Supplementary Figure S1: Two examples for batch
searches: On the top, the result page of a gene batch search for
the members of the HER-family. Here, the researcher used the
synonym “her2” and the unknown gene “her” for the ERBB2 gene. At the
bottom, the result page of the cell line batch search shows all mutations,
mutated genes, as well as the “non-mutated” genes.
Additional file 2: Supplementary Figure S2: Two examples for smart
searches: The “Mutation Status” smart search finds the mutations
of the HER-family, KRAS, and BRAF in five different cell lines. The
resulting matrix is shown in the blue box. The “Pathway Enrichment
Analysis” smart search determines for all KEGG pathways whether the
number of mutated genes found in prostate carcinoma samples is
statistically significant.
Additional file 3: Supplementary Figure S3: An advanced search for
all mutations of EGFR or ERBB2 in breast samples, which are no cell
lines. The found mutations and simple statistics are shown at the
bottom.
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